Open-Label Expanded Access for Ebola-Infected Patients to Receive Human MAb Ansuvimab As Therapeutic or for HR PEP

A Safety and Immunogenicity Study of Heterologous Prime-Boost Ebola Vaccine Regimens in Healthy Participants

NCT02313077 ·Status: COMPLETED ·Phase: PHASE1

Evaluating the Safety of and Immune Response to a Human Parainfluenza Virus Type 3 Ebola Virus Vaccine (HPIV3-EbovZ GP) in Healthy Adults

NCT02564575 ·Status: COMPLETED ·Phase: PHASE1

A Study to Evaluate A Range of Dose Levels of Ad26.ZEBOV and MVA-BN-Filo in Healthy Adult Participants

NCT02543567 ·Status: COMPLETED ·Phase: PHASE3

A Prospective, Open Label, Phase 1 Safety Study of Passive Immune Therapy During Acute Ebola Virus Disease Using Transfusion of INTERCEPT Plasma Prepared From Volunteer Donors Who Have Recovered From Ebola Virus Disease

NCT02295501 ·Status: TERMINATED ·Phase: PHASE1

EBOla Post-Exposure Prophylaxis

NCT06841614 ·Status: NOT_YET_RECRUITING ·Phase: PHASE3

A Study to Evaluate the Immunogenicity, Safety and Tolerability of Ad26.ZEBOV and MVA-BN-Filo in Healthy Adult Participants

NCT02543268 ·Status: COMPLETED ·Phase: PHASE3

RU Anti-SARS-CoV-2 (COVID-19) mAbs in Healthy Volunteers

NCT04700163 ·Status: COMPLETED ·Phase: PHASE1

Evaluation of Safety and Immunogenicity of rVSVΔG-SEBOV-GP Vaccine in Adults With Good General Health

NCT05724472 ·Status: COMPLETED ·Phase: PHASE1

Study to Assess the Safety, Tolerability, and Pharmacokinetics of HFB30132A Against COVID-19 in Healthy Adults

NCT04590430 ·Status: COMPLETED ·Phase: PHASE1

To Assess the Safety and Tolerability of MTx-COVAB36 as a Therapeutic and Prophylactic Treatment Against COVID-19.

NCT05351437 ·Status: COMPLETED ·Phase: PHASE1

Trial Evaluating the Immunogenicity and Safety of an Adjuvanted Epstein-Barr Virus (EBV) Glycoprotein 350 Vaccine in EBV-seronegative Persons

NCT05683834 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

Safety and Immunogenicity Study of Recombinant Protein RBD Candidate Vaccine Against SARS-CoV-2 in Adult Healthy Volunteers (COVID-19)

NCT05007509 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

Ebola and Marburg Virus Vaccines

NCT00605514 ·Status: COMPLETED ·Phase: PHASE1

Immunology of Ebola Vaccine

NCT06100913 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

Experimental Ebola Vaccine Trial

NCT00072605 ·Status: COMPLETED ·Phase: PHASE1

Experimental Vaccine for Prevention of Ebola Virus Infection

NCT00374309 ·Status: COMPLETED ·Phase: PHASE1

A Study to Evaluate Safety, Tolerability, and Immunogenicity of V350A and V350B in Healthy Participants (V350-001).

NCT06655324 ·Status: RECRUITING ·Phase: PHASE1

Study to Evaluate Safety and Immunogenicity of a Prime-Boost Regimen of rVSV-Nipah Virus Vaccine Candidate PHV02 in Healthy Adult Subjects

NCT06221813 ·Status: COMPLETED ·Phase: PHASE1

A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants

NCT05831111 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1

Vaccine Treatment for Ebola Virus in Healthy Adults (V920-001)

NCT02269423 ·Status: COMPLETED ·Phase: PHASE1

A Study to Assess the Safety, Tolerability, and Pharmacokinetics of HFB30132A Against COVID-19 in Chinese Healthy Adults

NCT05275660 ·Status: COMPLETED ·Phase: PHASE1

A Extension Study to Evaluate the Safety, Tolerability, and Immunogenicity of UB-612 COVID-19 Vaccine

NCT04967742 ·Status: COMPLETED ·Phase: PHASE1

Safety and Immunogenicity of mRNA-1653, a Combined Human Metapneumovirus (hMPV) and Parainfluenza Virus Type 3 (PIV3) Vaccine, in Healthy Adults, and Children 12 to 59 Months of Age With Serologic Evidence of Prior Exposure

NCT04144348 ·Status: COMPLETED ·Phase: PHASE1

Impact of Delay Between Administration of Inmazeb Administration and Vaccination by Ervebo on Vaccine Immune Response on Healthy Volunteers

NCT05202288 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2

Safety and Immunogenicity of a Sub-unit Protein CD40.RBDv Bivalent COVID-19 Vaccine, Adjuvanted or Not, as a Booster in Volunteers.

NCT06255626 ·Status: RECRUITING ·Phase: PHASE1/PHASE2